ABIONYX Pharma Announces the Completion of a Contribution in Kind to the Company of 100% of the Capital of IRIS Pharma Holding, Fully Compensated by the Issue of New Shares at a Price of €3.60 Per Share to Become a Specialist of Bioproducts...
06 Décembre 2021 - 7:30AM
Business Wire
- IRIS Pharma becomes a subsidiary of ABIONYX Pharma and
remains independent in its service activities for major
pharmaceutical and biotech companies in the ophthalmology
sector
- A potential portfolio of 3 new biologic product candidates
that could enter into the clinical phase in 14 potential
indications in ophthalmology
ABIONYX Pharma Announces the Completion of a
Contribution in Kind to the Company of 100% of the Capital of IRIS
Pharma Holding, Fully Compensated by the Issue of New Shares at a
Price of €3.60 Per Share to Become a Specialist of Bioproducts in
Ophthalmology and Renal Indications
ABIONYX Pharma (FR0012616852 – ABNX – PEA PME
eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies for patients,
today announces the final completion of a contribution in kind to
the company of 100% of the capital of IRIS Pharma Holding, who owns
100% of Iris Pharma, one of the leaders specialized in preclinical
and clinical contract research services in the field of
ophthalmology. The transaction was fully remunerated by the
issuance of new ABIONYX Pharma shares at a price set at 3.60 euros
per share. The completion of the contribution in kind follows a
successful capital increase in cash via a private placement for an
amount of 4.2 million euros at a price of 3.60 euros per share.
About IRIS Pharma
IRIS Pharma is a French company, one of the world leaders in
preclinical and clinical research in the field of ophthalmology.
Founded in 1989 by Dr. Pierre-Paul ELENA and managed today by Yann
QUENTRIC, IRIS Pharma has been providing services in the
development of ophthalmic drugs and ocular medical devices to
pharmaceutical industries, biotechnology companies and research
institutes worldwide (Europe, North America, Asia) for more than 30
years. Having participated in the development of more than 70
ocular drugs and medical devices currently on the international
market, IRIS Pharma is recognized as one of the world's leading
experts in the ophthalmic community.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211205005035/en/
NewCap Investor relations Louis-Victor Delouvrier
abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
